Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease.
Saved in:
| Title: | Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease. |
|---|---|
| Authors: | Raguraman V; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States., Mysinger M; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States., Verma M; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States., Mohiyuddin S; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States., Jabbour N; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States., Kesler M; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States., Joshi T; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.; Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri, Columbia, MO, United States., Palaniyandi S; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States., Hildebrandt GC; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Jun 11; Vol. 17, pp. 1843217. Date of Electronic Publication: 2026 Jun 11 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1843217 |
